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Abstract
Background: The incidence of breast cancer has increased since the 1970s. Despite favorable trends in prognosis,
the role of changes in clinical practice and the introduction of screening remain controversial. We examined breast
cancer trends to shed light on their determinants.
Methods: Data were obtained for 8502 new cases of breast cancer in women between 1985 and 2012 from a
population-based cancer registry in Granada (southern Spain), and for 2470 breast cancer deaths registered by the
Andalusian Institute of Statistics. Joinpoint regression analyses of incidence and mortality rates were obtained.
Observed and net survival rates were calculated for 1, 3 and 5 years. The results are reported here for overall
survival and survival stratified by age group and tumor stage.
Results: Overall, age-adjusted (European Standard Population) incidence rates increased from 48.0 cases × 100,000
women in 1985–1989 to 83.4 in 2008–2012, with an annual percentage change (APC) of 2.5% (95%CI, 2.1–2.9) for
1985–2012. The greatest increase was in women younger than 40 years (APC 3.5, 95%CI, 2.4–4.8). For 2000–2012
the incidence trend increased only for stage I tumors (APC 3.8, 95%CI, 1.9–5.8). Overall age-adjusted breast cancer
mortality decreased (APC − 1, 95%CI, − 1.4 – − 0.5), as did mortality in the 50–69 year age group (APC − 1.3, 95%CI,
− 2.2 – − 0.4). Age-standardized net survival increased from 67.5% at 5 years in 1985–1989 to 83.7% in 2010–2012.
All age groups younger than 70 years showed a similar evolution. Five-year net survival rates were 96.6% for
patients with tumors diagnosed in stage I, 88.2% for stage II, 62.5% for stage III and 23.3% for stage IV.
Conclusions: Breast cancer incidence is increasing – a reflection of the evolution of risk factors and increasing
diagnostic pressure. After screening was introduced, the incidence of stage I tumors increased, with no decrease in
the incidence of more advanced stages. Reductions were seen for overall mortality and mortality in the 50–69 year
age group, but no changes were found after screening implementation. Survival trends have evolved favorably
except for the 70–84 year age group and for metastatic tumors.
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Background
Breast cancer is the most frequent tumor in women
worldwide, particularly in countries with a high Human
Development Index [1]. Moreover, it is one of the lead-
ing causes of cancer mortality in females. In 2015 there
were 2.4 million estimated new cases and 523,000 esti-
mated deaths worldwide in women, which correspond to
about 29% of the total incident cancer cases and 14% of
all cancer deaths [2]. There is huge variability in the in-
cidence among countries, from 27 cases per 100,000
women in Asia to 97 per 100,000 white women living in
the USA [3]. In Spain, the 2015 age-standardized inci-
dence rate referred to the world population (ASR-W)
was 65.2 per 100,000 women and the age-standardized
incidence rate referred to the European population
(ASR-E) was 88.3 per 100,000 women, placing this coun-
try in an intermediate position worldwide [4].
Several industrialized countries including Spain have
shown a 30 to 40% increase in breast cancer incidence since
the 1970s [3, 5]. This rise has been related to the spread of
environmental and lifestyle risk factors, and to changes in
diagnostic patterns [3, 6, 7]. A trend change has been ob-
served since the beginning of the twenty-first century,
mainly among women older than 50 years [8–10]. The
main factors related to this change are the implementation
of population-based screening programs at a country-wide
level, and (albeit with a relatively low impact in Spain), the
evolution of prescribing practices for hormonal replace-
ment therapy [8, 11]. Analysis of breast cancer incidence
trends in young women vary widely among countries, but
in general show a steady increase since the early 1980s even
in countries where the incidence in older age groups has
decreased [12–14]. Studies in European countries and in
the US show an increase in the incidence of early-stage tu-
mors and a parallel reduction in late-stage tumors, although
this reduction seems to be smaller than expected and the
incidence of metastatic breast cancer has remained stable
[15–18]. In Spain, there are no available population-based
data on breast cancer incidence trends by stage.
Breast cancer mortality in Europe showed an increas-
ing trend until the 1990s [3]. Between 1989 and 2006,
breast cancer mortality (ASR-E) in European countries
reportedly declined by a median of 19% [19]. The
world-standardized mortality rate in Europe decreased
from 21.3 in 1990 [20] to 16.7 deaths per 100,000
women in 2007 [21]. Finally, in Spain, the mortality rate
(ASR-W) dropped from 17.3 per 100,000 women in
1995 to 10.8 per 100,000 in 2014 [22]. This reduction in
mortality has been consistently smaller in women older
than 70 years [5, 19], and correlates with the develop-
ment of adjuvant treatments and, to a lesser extent, with
the introduction of screening [23, 24].
Survival rates for breast cancer have generally in-
creased since the 1980s. This trend has been related with
a higher proportion of cases diagnosed at earlier stages as
well as therapeutical improvements [25]. Currently, the
5-year net survival rate is higher than 85% in seventeen
countries worldwide. In Europe the median survival rate
ranges from 81 to 84%, with the exception of Eastern
countries, where the survival rate is around 69% [26, 27].
However, no relevant increase in overall survival has been
observed for metastatic tumors, or in the group of women
older than 70 years [26, 28]. Spain had a 5-years survival
rate of 78.4% for women diagnosed between 1997 and
1999, and this rate increased to 82.8% for those diagnosed
between 2000 and 2007 [29]. Increasing trends in survival
are related to early diagnosis and improvements in surgi-
cal and adjuvant treatments. Several recent studies have
improved our understanding about the role played by
screening, the spread of adjuvant treatments and their ad-
verse effects, but there is still considerable controversy on
this issue [30–32].
Since 1985 the Granada Cancer Registry (southern Spain)
has systematically compiled data on breast cancer inci-
dence, mortality, and crude and net survival trends. We
were able to use the data collected for a period of more
than 28 years from 1985 to 2012. In addition, we analyzed a
subset of the data for the years 2000 to 2012, after the im-
plementation of a screening program in 1998. For this
period, we analyzed breast cancer incidence trends accord-
ing to disease stage, to shed light on the impact of screen-
ing on stage distribution and its association to mortality
and survival trends. To date no such analysis has been
undertaken in Spain, as far as we are aware.
Determinants of breast cancer trends have been
identified in previous studies, but unresolved contro-
versies remain about their role. Trends studies provide
an excellent opportunity to explore the specific weight of
each factor. Studies at regional or national level frequently
only consider either incidence or mortality [8, 15, 33, 34].
However, we present a comprehensive population-based
analysis of breast cancer epidemiology, including every in-
dicator and age group – an approach which facilitates an
integral interpretation of the factors that may influence
trends. Moreover, our analysis of tumor stages at diagno-
sis, together with the long observation period, hold the
potential to provide a better understanding of trend deter-
minants and especially the influence of breast cancer
screening.
Methods
Participants and data sources
The population data were from the Granada Cancer
Registry, a population-based cancer registry in southern
Spain launched in 1985 and covering a population of
about 922,100 inhabitants (50.3% women) (2011 popula-
tion census of Granada. Source: Statistics and Cartography
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Institute of Andalusia http://www.juntadeandalucia.es/
institutodeestadisticaycartografia).
A total of 8502 women residing in Granada province
were diagnosed with a first primary invasive breast can-
cer, and 2470 breast cancer deaths were registered be-
tween January 1st 1985 and December 31st 2012. The
Granada Cancer Registry uses as information sources
public and private hospitals at the local and regional
levels, oncology and pathology department records, and
death certificates. Mortality data were extracted from the
database of the Institute of Statistics and Cartography of
Andalusia (http://www.juntadeandalucia.es/institutodeesta-
disticaycartografia). Other sources of information used,
when necessary and available, were the National Index of
Deaths (http://www.msssi.gob.es/estadEstudios/estadisticas/
estadisticas/estMinisterio/IND_TipoDifusion.htm), the So-
cial Security Database (http://www.seg-social.es/wps/portal/
wss/internet/EstadisticasPresupuestosEstudios/Estadisticas),
municipal census information, and hospital and primary
care records.
The data in this registry are published regularly in Can-
cer Incidence in Five Continents (CIFC) monographs. The
quality of the data is supported by good indicators: 96% of
breast cancer cases were confirmed histologically, and a
death certificate was the only source of information for
1.8% of the cases. Moreover, the Granada Cancer Registry
is a member of the European Network of Cancer Regis-
tries (ENCR) and the Spanish Network of Cancer Regis-
tries (REDECAN), and a collaborator in the EUROCARE
(http://www.eurocare.it/) and CONCORD studies (http://
csg.lshtm.ac.uk/research/themes/concord-programme/).
Study variables
Standard international procedures for cancer registries
and coding rules are used in the Granada Cancer Regis-
try. Breast cancer is defined as code C50 according to
the International Statistical Classification of Diseases
and Related Health Problems, 10th revision [35].
Age was stratified in 5-year intervals for standardization,
and in the following broader groups for specific analysis:
less than 40 years, 40–49, 50–69, 70–84, and 85 years or
more. These groups have been established to focus on
main topics concerning breast cancer trends, as has been
done in previous analyses [13, 36–38]. Tumor stage at
diagnosis was coded with the TNM system (6th edition
for 2000–2010 and 7th edition for 2010–2012). Every case
was re-coded according to the 7th edition [39].
Passive and active follow-up of cancer cases was carried
out from the date of diagnosis to the end of follow-up (31
December 2014), when vital status was ascertained. The
outcome variables were alive at the end of follow-up,
death including date of exitus for any cause, or censored
due to loss or incomplete follow-up.
Statistical analysis
The number of new cases and deaths, crude rates, and
age-standardized mortality and incidence rates referred to
the European population are reported here. ASR-E rates
were calculated by weighting age-specific incidence rates
to the standard European population, and are expressed
per 100,000 women-years. For incidence and mortality
rates, R software was used (https://www.r-project.org).
Joinpoint regression analysis [40] of age-standardized
or age-specific incidence or mortality rates was used to
estimate the annual percentage change (APC) in breast
cancer incidence and mortality. The APC was calculated
by fitting connections between log scale linear trends to
the chronological year as the regressor variable, assum-
ing constant variance and uncorrelated errors. In the re-
gression analysis, up to three change points (four trend
line segments) were allowed. Each trend line segment is
expressed by an APC value. When no change points
were found, only one APC value represented the trend
line for the whole period.
Joinpoint regression was performed on data from the
earliest available data until the last year of available data.
Stage at diagnosis was not systematically recorded in the
Granada Cancer Registry for any cancer until the year
2000. Therefore, Joinpoint analysis of breast cancer inci-
dence according to stage was only performed for the
period 2000–2012.
Increasing or decreasing trends were considered to
exist for p values < 0.05. The APC and 95% confidence
intervals (CI) were calculated for the whole population,
and for age groups (0–39 years, 40–49, 50–69, 70–84,
and 85 years or more) and by tumor stage at diagnosis
(2000 to 2012). For all statistical analyses we used the
Joinpoint regression program (v. 4.1.1) [40].
Observed survival was calculated with the
Kaplan-Meier method for 5-year periods from 1985 to
2009, and for the last 3-year period from 2010 to 2012.
Because comorbidities can influence death rates, net sur-
vival was also calculated. This was defined as survival for
cases in which breast cancer was the only cause of death.
Net survival was estimated with the Pohar–Perme
method [41] and cohort analysis. For 2010–2012, period
analysis was used because follow-up time was too short
for cohort analysis [42]. Survival (standardized and
non-standardized by age) was calculated for 1, 3 and
5 years from diagnosis. Survival estimates were limited
to ages 15–99 years, and we excluded cases for which a
death certificate was the only source of information and
those diagnosed on autopsy. Survival analysis was done
with the strs package for Stata software v. 14 [43].
The dataset of the population-based cancer registry is
registered as stipulated by law within the Spanish Data
Protection Agency (Agencia Española de Protección de
Datos. https://www.agpd.es). All data collected in the
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database for incidence, mortality and survival analysis
were anonymous, and no ethical approval was required.
Results
Incidence 1985–2012
During the period from 1985 to 2012, 8502 new cases of
breast cancer were registered among women living in
Granada province (Table 1). Breast cancer accounted for
25% of all cancer cases (excluding non-melanoma skin
cancer) in women during this time, and the median age
at diagnosis was 59 years. European age-standardized in-
cidence rates increased from 48 cases per 100,000
women in 1985–1989 to 83.4 per 100,000 women in
2008–2012 (Table 1), with a statistically significant APC
of 2.5% (95%CI, 2.1–2.9).
Incidence trends by age group at diagnosis for the whole
period showed an increase that was statistically significant
in every age group, but differences were seen among
groups (Fig. 1). A substantial proportion of cases (44.9%)
were diagnosed in women 50–69 years old, and the APC
was 3.0% (95%CI, 2.4–3.5). Age group 0–39 years
accounted for 7.7% of all new cases, but presented the
greatest increase (APC 3.5, 95%CI, 2.4–4.7). Positive
trends were found for groups 40–49 years (APC 2.3,
95%CI, 1.5–3.0), 70–84 years (APC 2.0, 95%CI, 1.3–2.7),
and 85 years and older (APC 3.2, 95%CI, 1.5–4.8) (Fig. 1).
Incidence 2000–2012
During this period 5120 new cases of breast cancer were
registered, and incidence overall and for every age group
showed a nonsignificant trend. An increase in incidence
was found for stage I tumors (APC 3.8, 95%CI, 1.9–5.8),
whereas a decrease was found for all other stages, al-
though none of them reached statistical significance
(Fig. 2). Distribution by stage showed that 35.0% of tumors
were diagnosed in stage I, and 39.0% in stage II. Only 4.8%
of all diagnoses were stage IV tumors. Distribution of
breast cancer cases according to stage at diagnosis is
shown by age group in Table 2 and by chronological year
in Table 3.
Mortality 1985–2012
The crude mortality rate for breast cancer during 1985–
2012 in Granada province was 20.9 deaths per 100,000
women, corresponding to 2470 deaths. There was a de-
crease in ASR-E mortality from 20.5 to 15.2 per 100,000
women from 1985 to 1989 to 2008–2012 (Table 1). The
mortality trend during the study period showed an an-
nual decline (APC − 0.9, 95%CI, − 1.4 – − 0.5).
Breast cancer deaths occurred mostly in women older
than 70 years, and this age group contributed 45.3% of
all deaths. However, only women older than 85 years
showed an increasing trend in mortality (APC 3.7,
95%CI, 1.6–5.9) (Fig. 3). The rest of the age groups
showed non-significant decreasing trends for this period,
except the 50–69 year age group trend (APC − 1.3,
95%CI, − 2.2 – − 0.4).
Mortality 2000–2012
The overall trend for this period showed a nonsignificant
annual decrease of 0.7%. Stratification by age group
showed a nonsignificant increasing trend in women aged
40–49 years (APC 4.2, 95%CI, − 1.8 – 10.4) and 85 years
or more (APC 1.8, 95%CI, − 2.3 – 6.1). The number of
deaths in these groups was 132 in the former and 180 in
the latter (Table 4).
Survival 1985–2012
Both the observed and net age-standardized survival
rates at 5 years increased steadily from 67.5% in 1985–
1989 to 83.7% in 2010–2012 (Table 5). The evolution of
survival rates 1, 3 and 5 years after diagnosis are illus-
trated in Fig. 4.
Age group analyses showed that survival tended to in-
crease in groups younger than 70 years, with similar sur-
vival rates of approximately 90% in 2005–2009 and 93%
Table 1 Breast cancer mortality and incidence rates, and numbers of cases and deaths, 1985–2012
Period Incidence Mortality
Cases ASR-E* ASR-W* Deaths ASR-E* ASR-W*
1985–1989 909 48.0 36.0 408 20.5 14.8
1990–1994 1110 56.1 42.2 396 18.5 13.1
1995–1999 1363 64.1 47.7 420 17.9 12.6
2000–2004 1751 77.3 57.7 462 17.0 11.7
2005–2009 2051 81.0 60.5 485 16.5 11.6
2010–2012 1318 80.1 59.4 299 15.2 10.4
2000–2012 5120 79.5 59.3 1.246 16.5 11.4
1985–2012 8502 68.2 50.9 2.470 17.7 12.4
Numbers of cases and deaths, and age-standardized incidence and mortality rates (ASR-E and ASR-W) are shown for each period analyzed and for the first and
last 5-year follow-up. Population: 463816 women residing in Granada province (Source: 2011 population census for Granada, Statistics and Cartography Institute of
Andalusia). ASR-W: age-standardized rate referred to world population; ASR-E: age-standardized rate referred to European population. * per 100,000 women
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in 2010–2012. For women 70 to 84 years old, survival
increased to 70% until 1995–1999, and then remained
stable (Fig. 5). The 85–99 year age group showed a con-
stant increase in 5-year survival from approximately 20%
in 1985–1989 to 60% in 2010–2012. This group
accounted for the smallest number of deaths.
Survival 2000–2012
Analysis by stage for the final twelve years of our study
period disclosed important differences in survival related
with disease progression from the moment of diagnosis.
Net survival rates at 5 years were 96.6% in patients
whose tumor was diagnosed in stage I, 88.2% for stage II
tumors, and 62.5% for stage III tumors. The survival rate
decreased markedly to 23.3% in women with stage IV tu-
mors (Table 6).
Discussion
The results we obtained here with data from the Gran-
ada Cancer Registry show a steady increase in breast
cancer incidence between 1985 and 2012, with the great-
est rise in women younger than 40 years and in the age
group targeted for screening: 50–69 years. The decrease
in breast cancer mortality and the upward trend in sur-
vival support a general improvement in prognosis. At
the end of follow-up, women older than 84 years and
those with metastatic spread at diagnosis were the
groups showing the worst results.
From 1985 to 2012, the incidence of breast cancer in
our population has increased, as documented by the
APC of 2.5%. A similar increasing trend was observed
in Europe, with APCs ranging between 0.8 and 3% [44].
The introduction of the screening program may have
played an important role in this trend, as has been sug-
gested in previous European studies [8, 10, 15–17, 36,
45, 46].
However, this trend started in our analysis before
screening introduction and could also be found in age
groups not invited to the program. These findings have
been previously interpreted as indicators of the role played
by environmental, lifestyle and behavioral exposures [3, 5,
8, 16, 23, 44, 45, 47–50]. Several breast cancer reproduct-
ive risk factors such as parity, advanced age at first birth
or breast feeding have been highlighted before [51, 52], as
well as lifestyle risk factors including alcohol consump-
tion, post-menopausal obesity and sedentarism [53, 54].
Moreover, these finding have also been connected to
changes in diagnostic practices, that have increased detec-
tion rates [10, 12, 16, 24, 45, 48], like the increasing use of
opportunistic screening [55–57].
Fig. 1 Age-specific incidence trends for breast cancer, 1985–2012. Joinpoint regression analysis of age-specific trends in breast cancer incidence
rates per 100,000 for 1985–2012. APC estimates calculated by Joinpoint regression analysis. No change points were found. Population: 463816
women residing in Granada province (Source: 2011 population census for Granada, Statistics and Cartography Institute of Andalusia). * p < 0.05
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Finally, trying to disentangle the role played by screening
program implementation in the increasing incidence from
1985 to 2012 shown in our population, we have performed
a comparative analysis of overall and 50–69 year age group
incidence trends before and after screening program intro-
duction in our population in 1998. Incidence after 1998
showed a tendency to stabilization in overall analysis, even
though trend showed a significant increase for both periods
(1985–98 APC 2.9%, 1998–2012 APC 1.1%). Analysis of
age group 50–69 years showed a positive, though
non-significant trend after 1998 (1985–98 APC 2.8%,
1998–2012 APC 1.3%). These results suggest the influence
of other determinants besides the screening program on
the incidence trend shown from 1985 to 2012.
At the beginning of the twenty-first century, a change
in this rising trend was seen in many European countries
and in the USA. Screening programs initially led to a
temporary increase in the incidence, followed by a de-
crease to pre-screening levels. This phenomenon is re-
lated to the diagnosis of silent prevalent cases in the first
round and the need to wait until new incident cases
occur in the screened population [44]. Moreover, a drop
in breast cancer incidence correlated temporarily with
the drastic reduction in menopausal hormone therapy in
Fig. 2 Age-standardized trends in breast cancer incidence according to tumor stage, 2000–2012. Joinpoint regression analysis of age-
standardized trends in breast cancer incidence rates per 100,000 (referred to the European Standard Population) according to tumor stage at
diagnosis for 2000–2012. APC estimates calculated by Joinpoint regression analysis. No change points were found. Age-standardized rates
referred to the European population. Population: 463816 women residing in Granada province (Source: 2011 population census for Granada,
Statistics and Cartography Institute of Andalusia). * p < 0.05
Table 2 Tumor stage distribution by age group, 2000–2012
Age group (years) I II III IV Unknown Total
< 40 108 (29.1%) 172 (46.1%) 77 (20.6%) 12 (3.2%) 4 (1.1%) 373
40–49 360 (32.4%) 502 (45.2%) 192 (17.3%) 36 (3.3%) 21 (1.9%) 1111
50–69 991 (44.3%) 788 (35.3%) 312 (14.0%) 94 (4.2%) 49 (2.2%) 2234
70–84 296 (25.1%) 485 (41.2%) 264 (22.4%) 86 (7.3%) 47 (4.0%) 1178
≥85 31 (13.9%) 65 (29.2%) 70 (31.4%) 17 (7.6%) 40 (17.9%) 223
Overall 1792 (35.0%) 1998 (39.0%) 911 (17.8%) 243 (4.8%) 176 (3.4%) 5120
Number and percentage of breast cancer cases according to tumor stage and age group in 2000–2012. Percentages are rounded. Population: 463816 women
residing in Granada province (Source: 2011 population census for Granada, Statistics and Cartography Institute of Andalusia)
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many countries [8, 15, 58] after the results of the WHI
study were published [59]. These changes were observed
in overall analyses and in postmenopausal women [8, 15].
However, none of these changes was found in our analysis
of overall incidence, or in the 50–69 year age group.
A screening program in our population was intro-
duced in 1998, and the whole target population was in-
vited for the fifth round in 2002. In Granada the
screening participation rate has been higher than 70%
since 1999, and the median detection rate for the entire
Fig. 3 Age-specific mortality trends for breast cancer, 1985–2012. Joinpoint regression analysis of age-specific trends in breast cancer incidence
rates per 100,000 for 1985–2012. APC estimates calculated by Joinpoint regression analysis. No change points were found. Population: 463816
women residing in Granada province (Source: 2011 population census for Granada, Statistics and Cartography Institute of Andalusia). * p < 0.05
Table 3 Tumor stage distribution by chronological year, 2000–2012
Year I II III IV Unknown Total
2000 104 (30.6%) 144 (42.4%) 54 (15.6%) 22 (6.5%) 17 (5.0%) 341
2001 102 (29.7%) 152 (44.3%) 64 (18.7%) 15 (4.4%) 10 (2.9%) 343
2002 111 (28.0%) 173 (43.6%) 71 (17.9%) 24 (6.0%) 18 (4.5%) 397
2003 94 (28.8%) 125 (38.4%) 70 (21.7%) 18 (5.6%) 18 (5.6%) 325
2004 115 (33.7%) 137 (39.9%) 62 (17.8%) 17 (4.4%) 14 (4.1%) 345
2005 119 (34.7%) 134 (39.1%) 57 (16.6%) 23 (6.7%) 10 (2.9%) 343
2006 127 (32.6%) 148 (38.0%) 87 (22.4%) 14 (3.6%) 13 (3.3%) 389
2007 133 (32.4%) 155 (37.8%) 85 (20.7%) 20 (4.9%) 17 (4.1%) 410
2008 154 (36.9%) 165 (39.8%) 70 (16.9%) 13 (3.1%) 14 (3.4%) 416
2009 204 (41.5%) 192 (39.1%) 69 (13.9%) 16 (3.1%) 12 (2.5%) 493
2010 174 (41.8%) 134 (32.2%) 70 (16.9%) 18 (4.5%) 19 (4.5%) 415
2011 175 (37.8%) 168 (36.6%) 77 (17.0%) 31 (6.9%) 8 (1.7%) 459
2012 180 (40.5%) 171 (38.3%) 75 (16.9%) 12 (2.9%) 6 (1.3%) 444
Overall 1792 (35.0%) 1998 (39.0%) 911 (17.8%) 243 (4.8%) 176 (3.4%) 5120
Number and percentage of breast cancer cases according to tumor stage and chronological year in 2000–2012. Percentages are rounded. Population: 463816
women residing in Granada province (Source: 2011 population census for Granada, Statistics and Cartography Institute of Andalusia)
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study period was 3.5‰. These surrogate indicators con-
firm the good performance of screening in our setting,
according to the European Guidelines for Quality Assur-
ance in Breast Cancer Screening and Diagnosis [60]. In
light of this finding, the absence of changes in incidence
trends seems not to be related to a reduced or delayed
implementation of the program.
A previous study of the population analyzed here
showed a temporary rise in incidence until 2004, similar
to reports from other regions in Spain and consistent
with the diagnosis of prevalent cases [9]. The longer
follow-up period after screening introduction presented
in our paper reduced the likelihood of finding smaller
temporal trend changes in the Joinpoint analysis and
could explain the absence of changes in incidence trend
in our population. However, differences in age groups
definition between both analyses, due to changes in the
age range included in the Andalusian screening program,
could also have played a role.
Some specific characteristics of our population may par-
tially explain the absence of changes in temporal trends.
During the study period, hormonal replacement therapy
was prescribed to a lesser extent in Spain compared to
other European countries [11, 61], so the increase in inci-
dence during the 1990s and later decrease during the be-
ginning of the 2000s due to the usual prescribing patterns
were probably not as large as in other countries. Our set-
ting (southern Spain) is at a relatively low socioeconomic
level within the European Union, and this factor is known
to be associated with a lower incidence [1]. This circum-
stance may mean a smaller number of silent prevalent
cases at the beginning of the screening program, and
hence a less dramatic fall after screening began. Finally,
we should consider the effect of opportunistic screening
as a source of potential bias, as previously described by
international organisms [62]. This diagnostic practice
shows high detection rates, especially for early stage and
in-situ cancer [63], so it could have reduced the amount
of prevalent cases that otherwise would have been de-
tected in the first screening round [10]. No information is
available regarding the extent of opportunistic screening
in Granada province before or during our study period.
However, this practice has been proved to be common in
other countries [55], as well as in other regions of Spain
before screening program introduction [56, 57], and its ef-
fect over incidence trends have been considered in previ-
ous studies [45, 64].
To better understand the effects of population-based
screening, we undertook an analysis by tumor stage at
the time of diagnosis for the period from 2000 to 2012.
As expected, a statistically significant increase was ob-
served in stage I tumors at diagnosis. The age distribu-
tion confirmed that this increase occurred mainly in the
age group targeted for screening (50–69 years) – a trend
consistent with earlier diagnosis due to screening. How-
ever, the absence of a parallel decrease in advanced-stage
tumors in our distribution, has been attributed to the
non-progressive nature of a large proportion of tumors
potentially detectable by the program, and does not sup-
port this earlier diagnosis [17]. A favorable stage distri-
bution due to screening is suggested by the lower
proportion of stage III tumors in the screened age group
(50–69 years old), but no decreasing trend was seen for
this group in the Joinpoint analysis.
The decrease we observed in breast cancer mortality
was noted throughout the whole period analyzed here.
In Spain there has been a generalized decrease in mor-
tality since 1992, although there is some variability
among geographical regions [65]. This downward trend
started in our cohort before the screening program was
implemented, as in almost every region in Spain [65]
and in other European countries [23]. Hormonal treat-
ments and new polychemotherapy schemes were also in-
troduced during the 1990s, and together with the
increased use of effective radiotherapy regimens,
Table 4 Age-specific mortality trends for breast cancer in the
female population in Granada province, 2000–2012
N APC 95%CI
Total 1246 −0.7 −2.3 – 0.9
Age group (years)
00–39 35 −4.2 −12.0 – 4.2
40–49 132 4.2 −1.8 – 10.4
50–69 433 −2.7 −5.3 – 0.0
70–84 466 −1.2 −2.6 – 2.7
85 and over 180 1.8 −2.3 – 6.1
APC estimates calculated by Joinpoint regression analysis of age-specific
mortality rates, for 2000–2012. Population: 463816 women residing in Granada
province (Source: 2011 population census for Granada, Statistics and
Cartography Institute of Andalusia). APC: annual percentage change
Table 5 Trends in observed 5-year survival and age-
standardized net survival in women with breast cancer
Period n Observed survival Net survival (age-standardized)
OS 95%CI NS 95%CI
1985–1989 844 63.9 60.5 67.0 67.5 61.8 72.5
1990–1994 1087 67.5 64.6 70.2 69.6 64.7 73.9
1995–1999 1344 73.7 71.3 76.0 76.4 72.4 79.8
2000–2004 1721 77.0 75.0 79.0 78.9 75.7 81.8
2005–2009 2030 80.0 78.2 81.7 82.1 79.0 84.7
2010–2012a 1791 81.0 78.8 83.1 83.7 79.8 86.8
aPeriod analysis instead of cohort analysis was used
Estimates for observed survival calculated with the Kaplan-Meyer method, and
for net survival calculated with the Pohar–Perme method (cohort analysis) in
5-year periods from 1985 to 2012 and in the 3-year period from 2010 to 2012.
Age-standardized rates referred to the European population. Population:
463816 women residing in Granada province (Source: 2011 population census
for Granada, Statistics and Cartography Institute of Andalusia). OS: observed
survival; NS: net survival
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probably played an important role in this trend [24, 36,
45, 66–68]. Metanalysis of the effectiveness of clinical
trials with adjuvant treatments showed a marked reduc-
tion in breast cancer mortality, and in some cases, in
all-cause mortality [31, 32].
The favorable evolution of survival trends is consistent
with findings reported for other European countries [29]
and the USA [27]; these trends correlate with tumor stage
at diagnosis [69]. In our analysis, we found an increase in
stage I tumors during the 2000–2012 period. Despite this
favorable trend, survival did not increase in the 70–84 year
group or in the subgroup with metastatic tumors at diag-
nosis. Adjuvant treatment, one of the factors responsible
for this trend, is less effective for this stage and age group
[70]. Women older than 70 years also have more
comorbidities, and breast-conserving surgery plus
adjuvant therapy are used to a lesser extent; both of these
factors are related to decreased survival [71]. In the
85–99 year age group survival increased markedly from
23% in 1985–1989 to 62% in 2010–2012. However, the
small number of deaths in this age group precludes any
conclusions regarding this particular subgroup.
Mortality in women older than 70 years in Europe
has shown an increasing trend or a smaller decrease
than in younger age groups [19]. In our results,
mortality increased in this age group (data not
shown). This trend was also found for women older
than 84 years in a separate analysis. In the 70–
84 year and > 84 year age groups the proportion of
metastatic tumors was larger than in other age
groups (Table 2). Both older age and a greater pro-
portion of metastatic tumors are important factors
in the response to treatment. Moreover, women
older than 70 years are less likely to receive standard
treatment [72].
In our analysis of women younger than 40 years, the
incidence trend (APC 3.6%) was larger than the trend
reported for this age group in other European countries:
the European median APC is 1.2% [13]. There appear to
be no clear correlations between trends in this age group
and known risk factors [13]. In younger women at least
one earlier study found that factors related with tumor
biology were associated with a greater risk of death and
a worse prognosis [14].
Fig. 4 Age-standardized 1-, 3- and 5-year survival and net survival in women with breast cancer, 1985–2012. Estimates of observed survival
calculated with the Kaplan–Meyer method, and net survival calculated with the Pohar–Perme method (cohort analysis) for 1985–2012 in 5-year
periods and for the final 3-year period from 2000 to 2012. Period analysis was used instead of cohort analysis for the last 3-year period. Age-
standardized rates referred to the European population. Population: 463816 women residing in Granada province (Source: 2011 population
census for Granada, Statistics and Cartography Institute of Andalusia)
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Some authors have noted that changes in diagnostic
patterns with the increased use of mammography and
ultrasonography, along with wider access to MRI, are
likely to be important factors in the reported increases
in incidence among younger women [20]. In our study,
more than 75% of tumors were diagnosed at stages I–II,
and survival rates were similar to those in other age
groups. These findings are consistent with the concurrent
use of opportunistic screening in parallel with population-
based screening programs. The influence of opportunistic
screening was demonstrated in Barcelona, where 27.1% of
women younger than 40 years received routine screening
with mammography before a population-based program
was introduced [57]. Moreover, 23.5% of women younger
than 45 years reported having a mammography examin-
ation in 2014 [73], and 5% of this age group had visited a
gynecologist for reasons other than pregnancy in the previ-
ous year [74]. Unfortunately, the lack of information re-
garding hormonal receptors and HER2 overexpression
prevented us from analyzing these trends according to
pathologic subtypes.
The decrease in overall mortality in Europe is reportedly
greater in women younger than 50 years [19], and inter-
national studies confirm greater mortality with advancing
age [5]. In our cohort, the 0–50 year age group showed a
stable trend, in contrast to the decrease observed for
women 50 to 69 years old (data not shown). In a differen-
tial analysis of the 40–49 year age group, we also found no
statistically significant decrease. Previous research in
Spain, however, reported a decrease in mortality among
Fig. 5 Five-year age-specific net survival in women with breast cancer, 1985–2012. Estimates of net survival calculated with the Pohar–Perme
method (cohort analysis) for 1985–2012 in 5-year periods and for the final 3-year period from 2000 to 2012. Period analysis was used instead of
cohort analysis for the last 3-year period. Population: 463816 women residing in Granada province (Source: 2011 population census for Granada,
Statistics and Cartography Institute of Andalusia)
Table 6 Age-standardized net survival according to stage in
women with breast cancer, 2000–2012
Stage 1-year NS 3-year NS 5-year NS
I 99.9 98.3 96.6
II 99.7 95.1 88.2
III 91.4 75.3 62.5
IV 60.0 35.0 23.3
Unknown 92.3 77.4 75.4
Estimates for net survival calculated with the Pohar–Perme method (cohort
analysis), according to tumor stage at the time of diagnosis (TNM 7th
edition), 2000–2012
Age-standardized rates referred to the European population. Population:
463816 women residing in Granada province (Source: 2011 population census
for Granada, Statistics and Cartography Institute of Andalusia). NS: net survival
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women younger than 40 years [75], so the difference
between studies may reflect regional differences in inci-
dence. However, caution should be used when inter-
preting these results given that the number of deaths in
this age range is low.
The results of our analysis are strengthened by the in-
clusion of the most recent available data from the Granada
population-based cancer registry, which has been in oper-
ation for 25 years and holds data for approximately 9000
registered cases of invasive breast cancer. We used appro-
priate statistical methods to detect trend changes and to
calculated net survival rates. The high quality of the data
was ensured by quality control measures, e.g. microscopic
confirmation of the diagnosis in 96% of all registered
cases, only 1.8% of which recorded the diagnosis based
only on information from the death certificate.
Nevertheless, several limitations should be considered
when interpreting our findings. The Granada Cancer
Registry limits its target population to the provincial level,
with a total population of approximately 1 million people.
Population-specific characteristics need to be considered,
along with the low number of events for some analyses.
The absence of consistent information about risk factors
prevalence in our population has not permitted us to
present a direct interpretation of their role in time trends.
Because of the mentioned factors, the external validity of
our results may be limited, and the statistical power of
some analyses was insufficient to reach definitive conclu-
sions. In addition, lack of stage at diagnosis data before
year 2000 refrained us from performing Joinpoint regres-
sion of breast cancer incidence according to stage for the
whole period. Despite these limitations, this study pro-
vides population-based results for a long period of study,
documents for the first time the evolution of breast cancer
incidence according to stage at the time of diagnosis and
provides some clues regarding the effect of screening on
this important prognostic variable.
Conclusions
In conclusion, the data from a population-based cancer
registry in southern Spain show an increasing trend in
breast cancer incidence from 1985 to 2012. The in-
creases were greatest in the 0 to 49 and 50 to 69 years
age groups. No change points in incidence trends were
found in Joinpoint regression analysis for this period.
This evolution is consistent with the spread of risk fac-
tors and the rise in diagnostic pressure [3, 8, 16, 23, 36,
44, 45, 47, 55, 76]. Further analyses of incidence trends
determinants should be carried out, especially in young
women, for designing future prevention strategies. We
did not observe the previously turning point in incidence
at the beginning of the twenty-first century in our coun-
try [8–10, 77] and, as we have already discussed, several
causes may explain this difference.
Incidence trends by stage at diagnosis for the 2000–
2012 period show an increase in stage I tumors. The ab-
sence of an equivalent decrease in advanced stage tu-
mors suggests that at least a proportion of the tumors
detected thanks to screening are non-progressive, raising
doubts about screening effectiveness. However, the re-
duced proportion of stage III tumors in the 50–69 year
age group points to a favorable shift in stage distribu-
tion. It should also be considered that tumors identified
as metastatic at diagnosis represent a more aggressive
type of breast cancer that may not benefit from mam-
mographic screening, neither from advances in treat-
ment. Therefore, it is possible that specific prevention
strategies for metastatic breast cancer should be
developed.
Mortality decreased slightly during the 1985–2012
period, although analysis by age group showed that this
trend was statistically significant only in women aged
50–69 years. Although this is the age group the screen-
ing program is targeted to, the absence of any change in
trend after screening was introduced, and the lack of a
clear decrease in incidence during the 2000–2012
period, do not support a substantial beneficial effect.
The trend in survival of breast cancer in our setting has
evolved favorably except in the 70–84 year age group, in
which women more frequently receive non-standard treat-
ments, and in which the percentage of stage I tumors –
characterized by their better response to treatments – was
lower than in other age groups.
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